Isis upbeat on prospects for US Kynamro approval and promising pipeline
22:11 EDT 6 Aug 2012 | SCRIP
Following an upbeat second quarter earnings report on 6 August and guidance for the rest of the year, antisense drug developer Isis Pharmaceuticals announced an offering of $175 million of convertible senior notes to repurchase debt previously issue..
Original Article: Isis upbeat on prospects for US Kynamro approval and promising pipeline
More From BioPortfolio on "Isis upbeat on prospects for US Kynamro approval and promising pipeline"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
